Introduction
Prostaglandins play a key role in cellular proliferation and growth of both normal and aberrant cells. Furthermore, prostaglandins mediate the effects of several growth promoting factors and oncogenes. 1, 2 Two isoforms of cyclooxygenase (COX-1 and COX-2) are known rate-limiting enzymes involved in the production of prostaglandins from arachidonic acid precursors. 3 The constitutive cyclooxygenase (COX-1) is present in many tissues and synthesizes prostaglandins that are involved in maintaining normal tissue homeostasis. 4 The second isoform, COX-2, is responsible for prostaglandins produced in sites of inflammation and is induced by growth factors, cytokines, and various carcinogens. 5 Most importantly, COX-2 is also involved in mechanisms of carcinogenesis such as apoptosis, 6, 7 invasiveness, 8 adhesion, 9 and angiogenesis. 10 Several studies have indicated that COX-2 is upregulated in various cancers: breast, colon, lung, pancreas, esophagus, and prostate. [11] [12] [13] [14] [15] [16] [17] The promoter region of the COX-2 gene consists of various transcriptional regulatory elements which may have profound effects on expression of the enzyme. Major upstream transcriptional regulatory elements previously identified in the promoter include: a scaffold/matrix attachment region (S/MAR), C/EBP site, AP1-like site (AP1), GAS-binding site (STAT1), SIE-binding (STAT3), NFkappaB, AP2-like site (AP2), and a TBP-binding site (TFIID). 18 To elucidate the role of the COX-2 gene in prostate cancer development and progression, we examined DNA sequence variation in the COX-2 promoter in several clinically evaluated populations from three different ethnic groups. In order to better determine the role sequence variation plays in prostate cancer etiology it is important to examine diverse populations because of potential genetic and environmental differences among populations. These differences may contribute to the incidence of prostate cancer varying significantly across ethnic groups with African American men having the highest incidence of prostate cancer compared to other ethnic groups. In addition, age-adjusted mortality is two times higher for African American men than for European American men. 19 In this study we identified SNPs in the COX-2 gene promoter and performed genotype and haplotype association analyses on prostate cancer in African Americans, Nigerians and Europeans Americans. We observed strong but different patterns of associations between COX-2 SNP genotypes, haplotypes, and prostate cancer among the three ethnic groups. Our results provide evidence that sequence variation in the COX-2 promoter contributes to risk of prostate cancer.
Subjects
Unrelated men from three different ethnic groups were enrolled for case-control studies of risk factors for prostate cancer. All prostate cancer cases were between 40 to 85 years of age and were diagnosed with prostate cancer within the last 4 years. The first group consisted of two hundred and eighty-eight African Americans (124 prostate cancer patients and 164 healthy male controls) recruited from the Howard University Hospital (HUH) in Washington, DC. Incident cases were identified through the Division of Urology at HUH and confirmed by review of medical records. The participation response rate among the African American cases was 92%. Healthy control subjects matched for age were ascertained from the Division of Urology at HUH and also from men participating in screening programs for prostate cancer at the Howard University Hospital. The screening program was demographically similar to the patient population seen in the Division of Urology clinics. The recruitment of controls occurred concurrently with individuals recruited with prostate cancer. The participation response rate for the African American controls was 90%.
The second group of prostate cancer cases and controls consisted of one hundred and eighty-four European Americans (92 prostate cancer patients and 92 healthy male volunteers) recruited from the Johns Hopkins Hospital (Baltimore, MD). 21 The European American prostate cancer case subjects were recruited from the patients who underwent prostate cancer treatment at Johns Hopkins Hospital. The diagnosis of prostate cancer was confirmed by pathology reports. The response rate among the European American cases was 95%. European American control subjects were recruited from volunteers 3 participating in prostate cancer screening programs at Johns Hopkins Hospital. The response rate for the European American controls was over 90%.
A third group of prostate cancer cases and controls consisting of two hundred and sixty-four Nigerians (Edo State) (154 prostate cancer patients and 110 healthy male controls) belonging to the Bini ethnic group were enrolled through a community-based study of risk factors for prostate cancer in collaboration with the University of Benin Teaching Hospital (UBTH) in Benin City, Nigeria. 20 Incident cases were recruited during the years 2000 and 2001 at UBTH. During the two year period healthy controls were also ascertained from a prostate cancer screening program in the same community as UBTH. The Bini ethnic group represents 84.7% of the population in the Benin City community. The response rate among the Nigerian cases and controls were 88% and 85% respectively. Blood samples were collected from each subject. Clinical characteristics including Gleason grade, PSA, TNM stage, age at diagnosis and family history were obtained from medical records. Disease aggressiveness was defined as "Low" (T category < T2c and/or Gleason grade < 7) or "High" (T category ≥ T2c and/or Gleason grade ≥ 7). All healthy controls had PSA levels <4.0ng/ml and normal DREs. The Howard University Institutional Review Board approved the study and written consent was obtained from all subjects.
SNP discovery
Genomic DNA was isolated from lymphocytes by standard proteinase K digestion, cell lysis, protein precipitation, and DNA precipitation. One thousand four hundred base pairs upstream of the ATG start site of the COX-2 gene was screened for DNA sequence variation by denaturing high performance liquid chromatography (dHPLC) using the Wave TM DNA fragment analysis system (Transgenomic Inc, CA) according to manufacturer's instructions. Five sets of primers used to amplify COX-2 promoter fragments for SNP discovery were AM1F 5'-GCT GTC AAA ATC TCC CTT CC-3' and AM1R 5'-TTT CTC TCC CTG ATG CGT GG-3'; AM2F 5-AGT AAC CAA AAT AAT CCA CGC-3' and AM2R 5'-TAC CTT CAC CCC CTC CTT G-3'; AM3F 5'-TTA CCT TTC CCG CCT CTC-3' and AM3R 5'-GTT TTA TGT TTT AGT GAC GAC GC-3'; AM4F 5'-GCT ATG TAT GTA TGT GCT GC-3' and AM4R 5'-GCT TCC GAG AGC CAG TTC-3'; AM5F 5'-CGG TAT CCC ATC CAA GGC-3' and AM5R 5'-TGC TCC TGA CGC TCA CTG-3'. Genomic DNA from twenty individuals (ten prostate cancer cases and ten controls) from each of the three populations (total 60) were used for SNP discovery. We detected four polymorphisms, -1285A/G, -1265G/A, -899G/C and -297C/G, (dbSNP # ss5112604, ss5112605, ss5112606, and ss5112607, respectively).
Genotyping
The -1265G/A SNP was genotyped by direct DNA sequencing from the PCR product using fluorescent labeled Big Dye sequencing chemistry (ABI) and the ABI 377 DNA sequencer (Foster City, CA). Genotyping of the -1285A/G, -899G/C and -297C/G polymorphisms was performed using Pyrosequencing TM (Pyrosequencing, AB) according to standard protocols. 22 PCR amplification of the -1285A/G SNP used a forward primer, 5'-TTC CAG CTG TCA AAA TCT C-3' and a biotinylated reverse primer, 5'-biotin-AAG ATT ATG AGT TGT GAC C-3'; for the -1265G/A SNP, forward primer 5'-ATC TCC CTT CCA TCT AAT-3' and reverse primer 5'-TGG TAA AAA TAA ATT CGA GT-3'; for the -899G/C SNP, forward primer 5'-ACA GGG TAA CTG CTT AGG-3' and biotinylated reverse primer 5'-biotin-CTC CTT GTT TCT TGG AA-3'; and for the -297C/G SNP, forward primer 5'-AGA CAG GAG AGT GGG GAC-3'and reverse biotinylated primer 5'-biotin-GGG GGC AGG GTT TTT TAC-3'. Pyrosequencing primers were as follows: 5'-CCA AAA CGA GAA TA-3' for -1285A/G; 5'-GAG GAG AAT TTA C-3'for -899G/C; and 5'-TTC CGA TTT TCT CAT T-3' for -297C/G. Genotyping of these three SNPs were performed using the PSQ96 automated Pyrosequencing instrument (Pyrosequencing AB, Uppsala, Sweden). All samples were genotyped twice directly from genomic DNA. Control DNAs included known wild-type homozygotes, heterozygotes and variant homozygote 4 sample genotypes. The control DNAs were confirmed by direct DNA sequencing using an ABI 377 DNA sequencer (ABI, Foster City, CA). Genotypes from the repeat assay were 100% concordant with initial genotypes.
Haplotype construction and statistical analyses
Genotype and allele frequencies were calculated for each population. Hardy-Weinberg equilibrium analysis of each group was evaluated by contingency table analysis. COX-2 haplotypes were estimated from the marker genotypes by a maximum likelihood method using the computer program MLOCUS (written by J. Long), which implements the EM algorithm. 23, 24 The MLOCUS program was also used to calculate pairwise linkage disequilibrium (D') for each marker pair. Odds ratios and P values were determined by multiple logistic regression analyses from comparison of genotypes or haplotypes between prostate cancer patients and healthy controls using SAS version 6.12 (SAS Institute, Inc, Cary, NC.). Analyses were initially performed on the combined dataset consisting of all three populations. For all analyses of the combined dataset, genetic effects were adjusted for the potential confounders such as ethnicity, age (at time of diagnosis for case subjects and at time of ascertainment for controls) and family history (defined as one or more first degree relatives). Since there may be specific genetic effects within different populations (environments), analyses were also performed for individual ethnic groups. Table 1 describes the patient populations. Mean ages for cases and controls differed across but not within the three ethnicity groups. There were no significant differences in the distribution of PSA levels between African Americans and European Americans, however subtle differences were evident between African Americans and European Americans for mean age at diagnosis and family history of prostate cancer. The percentage of men with family history for prostate cancer was much higher for African Americans. Nigerian subjects were much older, exhibiting more aggressive disease and much higher PSA than their US counterparts.
Results
Four SNPs were identified in the COX-2 gene promoter (-1285A/G; -1265 G/A; -899 G/C; and -297 C/G). The -899C SNP was previously reported in a genetic study on familial adenomatous polyposis (FAP). 25 Table 2 shows allele frequencies of the four polymorphisms in the three normal control populations. Significant differences in allele frequencies (P<0.01) were observed for the -1285G, -1265A and -899C SNPs between African Americans and the other two populations (Table 2 ). Putative changes in transcription factor binding sites due to these SNPs were evaluated by computer prediction using the Alibaba2 program. 26 Table 3 shows the various transcription factor binding sites that were created or lost due to the four polymorphisms in the COX-2 gene promoter.
Genotype frequencies are shown in table 4. All genotypes were in Hardy-Weinberg equilibrium for each population (P>0.05; data not shown). Allele and genotype frequencies for African Americans were intermediate between Bini Nigerians and European Americans for all four SNPs. Analyses of the markers in the combined dataset controlling for ethnicity, age at diagnosis and family history revealed that the presence of the -297G allele decreased risk for prostate cancer (odds ratio [OR] = 0.49; 95% CI = 0.2-0.9). Subset analyses of the different ethnic groups revealed the effects of -297 CG/GG genotypes on prostate cancer risk in African Americans (OR=0.51; 95% CI=0.2-0.9; P=0.01) and similarly among European Americans (OR= 0.33; 95% CI= 0.08-0.89; P=0.02).
Analyses of the other three SNPs in the combined dataset did not indicate an association with prostate cancer (Table 5 ). However in subset analyses with the African American population, -1265 GA/AA genotypes were associated with increased prostate cancer risk (OR=2.72; 95% CI=1.3-5.8; P=0.007). In addition, individuals with at least one copy of the -899C allele were at increased risk for prostate cancer in the African American population (OR= 3.67; 95% CI 1.4-9.9; P=0.007) ( Table 5 ). Due to the low frequency of the -1265A and -899C SNPs in the European American population there lacked sufficient power to determine an association with the disease.
Altogether six haplotypes comprise >97% of all chromosomes observed in the African American and Nigerian populations (Table 4) . However, only two haplotypes accounted for 99% of the European American chromosomes. Pairwise LD analyses revealed moderate to strong LD across marker pairs for all populations. No significant differences in pairwise LD patterns existed between prostate cancer cases and controls. Haplotype AGGC was the most common haplotype among all populations ranging from 52% to 93% in Nigerian and European American controls populations respectively.
Haplotype AGGG was significantly more common among controls subjects (8%) than cases (4%) in the combined dataset (Table 4 ). This pattern was observed across all three ethnic groups. Table  6 shows that even after controlling for ethnicity, age and family history of prostate cancer, haplotype effects were observed in the combined dataset for haplotypes AGGG (OR=0.4; CI=0.2-0.7; P=0.002) and GGCC (OR=1.4; CI=1.1-2.2; P=0.04). These effects were also observed in the subset analyses of the ethnic groups. Specifically, haplotype AGGG was negatively associated with prostate cancer in African Americans and European Americans (OR=0.4; CI= 0.1-0.9; P=0.02 and OR= 0.2; CI=0.1-0.9; P=0.03, respectively). Among African Americans, the frequency of haplotype AGGG was 3% for affected men and 9% for controls. Likewise, the frequency for haplotype AGGG among European Americans was 2% for affected men and 6% for controls. Among the Bini Nigerians with haplotype AGGG, the trend was similar (6% of cases and 9% of controls), yet not significant (P=0.58).
Subset analyses also revealed that haplotype GGCC was strongly associated with prostate cancer in African Americans (OR=4.5, CI 1.3-16; P=0.01) and Nigerians (OR=3.9, CI=1.1-19; P=0.003). Additionally, African Americans possessing haplotype AACG exhibited increased risk for prostate cancer (OR=2.5; CI=1.2-5.1; P=0.006). Analyses in which we stratified all prostate cancer cases according to disease aggressiveness, age at diagnosis and family history revealed no significant correlations with individual SNPs, haplotypes and the disease (data not shown).
Discussion
Numerous studies suggest a role for COX-2 in carcinogenesis. [6] [7] [8] [9] 11, 14 However little is known about the role sequence variation within the COX-2 gene plays in prostate cancer risk. This is the first genetic study that explores the impact DNA sequence variation within the COX-2 promoter has in prostate cancer risk in diverse ethnic groups. In this study, we identified four SNPs within a 1.4 kilobase region upstream of the COX-2 gene ATG-site. We utilized single SNPs and haplotypes for a casecontrol association study on prostate cancer risk. Since the four SNPs were in close proximity (less than 1kb) we observed strong linkage disequilibrium in the populations. Thus the four SNPs were not independent of each other and likely carry similar information about risk. By evaluating the single markers collectively as haplotypes the SNP associations were confirmed. However, our results should be viewed with caution since association studies using unrelated controls may be affected by population stratification. Population stratification occurs when residual confounding by ethnicity remains due to unidentified ethnic differences between cases and controls. However, it is unlikely that population stratification caused confounding in this study since an unlinked marker analysis consisting of 20 SNPs with large differences in allele frequencies between west African and European ancestry within three populations revealed no significant differences between cases and controls (R.A.K., W.C., and L.L., unpublished observations).
Patterns of COX-2 haplotype variation differed between populations. Populations of African descent possessed more than twice the number of haplotype observed among European Americans. This observation of higher haplotype variation among African descent populations is consistent with studies which focus on variation at other genetic markers. 21, 27 Greater genetic diversity in African populations may have broad implications on our understanding of genetic diseases and the common disease/ common variant (CD/CV) hypothesis. [28] [29] [30] The presence of the same haplotypes conferring risk in 6 different populations provides intriguing evidence for the involvement of COX-2 in prostate cancer risk. However, this study also revealed that different COX-2 haplotypes were implicated in prostate cancer risk in the different populations. For instance, for African Americans and Bini, Nigerians, the GGCC haplotype increased the risk for prostate cancer, while in African Americans and European Americans, a different haplotype, AGGG, likely contributes protective effects. It is possible that other causative genetic variants may lie either upstream or downstream of the SNP markers found in our study. In addition we note that there may be other limitations in this study. Besides small sample sizes in the subset analyses, the functional significance of these sequence polymorphisms is lacking.
Recently, the prostate cancer susceptible gene, 2'-5'-oligoadenylate (2-5A)-dependent RNase L (RNASEL) was mapped by Carpten et al. 31 [OMIM 180435 ] to the HPC1 locus on the chromosome 1 (1q24-25). Interestingly, the COX-2 gene is also mapped to the same region on chromosome 1 (1q25.2). Since COX-2 is located close to HPC1 and RNASEL was recently associated with sporadic disease, 32 we also typed several common RNASEL SNPs (-95T/C, 1385G/A, and 1623T/G) in our populations and did not observed any associations. Thus, it would be of interest to explore the involvement of COX-2 gene in HPC.
DNA sequences upstream of the COX-2 translation initiation site possess multiple putative transcription factor binding sites. Of the SNPs observed in the study populations, two (-1265A and -297G) lead to the creation of two new transcription factor binding sites while one polymorphism (-899C) eliminates a transcription factor binding site (see table 2 ). The -1265A SNP eliminates a CCAAT/Enhancer Binding Protein alpha binding site (C/EBPα) on the COX-2 promoter and creates Pit1a and Hb binding sites. C/EBPα regulates cell proliferation and gene expression. [33] [34] [35] In vivo studies on mice reveal that the loss of C/EBPα results in a 20-55% decrease in the transcription of COX-2 gene. 36 The -899C SNP is within a Sp-1 binding site, but does not appear to change the consensus binding site, however, a NF-kB site is eliminated upstream of the SP-1 binding site. Multiple studies have shown that COX-2 is over expressed in prostate cancer cells, 15, 37 and that the induction of COX-2 expression is mediated by NF-kB. 38 Our study reveals the complexity of multiple SNP analyses where different SNPs may alter transcriptional binding sites. What may be a protective SNP in one population may appear to increase risk in another population due to other linked polymorphisms which may exhibit stronger effects on gene function. For instance, the -297G allele creates two new sites, a ribosomal DNA enhancer binding protein 1 (REB1) site, and a C/EBPδ site that plays an important role in cell cycle growth arrest in mammary epithelial cells and fibroblasts. 39 Thus the creation of the new binding sites due to the -297G allele may be protective against tumorogenesis and hence be negatively associated with prostate cancer risk. If the above predicted changes in the transcription factor binding sites are valid, they could have major consequences for the expression of COX-2. Functional studies or expression studies in tumor tissues of known COX-2 haplotypes are strongly warranted in order to fully answer the various points discussed here.
The close proximity, strong LD, possible regulatory significance, and the ability to construct haplotypes using COX-2 promoter SNPs increased our power to evaluate the role variation in the COX-2 gene plays in prostate cancer risk. Our results reveal a complex pattern of COX-2 haplotype associations with prostate cancer. The complex pattern of haplotype association is mainly due to polymorphisms within transcription binding sites segregating on different haplotypes. Haplotypes with the nucleotide C at the -899 position of COX-2 promoter appear to increase susceptibility and haplotypes with G at the -1285 position appear to have a protective effect. These observations clearly require further detailed investigation of the functional and expression consequences of the COX-2 promoter SNPs. OR adjusted by multiple logistic regression for ethnicity, age and family history of CaP
